XML 62 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Earnings Per Common Share Attributable To Mylan Inc.
9 Months Ended
Sep. 30, 2012
Earnings Per Share [Abstract]  
Earnings per Common Share Attributable to Mylan Inc.
Earnings per Common Share Attributable to Mylan Inc.
Basic earnings per common share is computed by dividing net earnings attributable to Mylan Inc. common shareholders by the weighted average number of shares outstanding during the period. Diluted earnings per common share is computed by dividing net earnings attributable to Mylan Inc. common shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.
On September 15, 2008, concurrent with the sale of $575 million aggregate principal amount of Cash Convertible Notes due 2015 (the “Cash Convertible Notes”), Mylan entered into a convertible note hedge and warrant transaction with certain counterparties. Pursuant to the warrant transactions, the Company sold to the counterparties warrants to purchase in the aggregate up to approximately 43.2 million shares of Mylan common stock, subject to anti-dilution adjustments substantially similar to the anti-dilution adjustments for the Cash Convertible Notes, which under most circumstances represents the maximum number of shares that underlie the conversion reference rate for the Cash Convertible Notes. The sold warrants had an exercise price of $20.00 and will be net share settled, meaning that Mylan will issue a number of shares per warrant corresponding to the difference between its share price at each warrant expiration date and the exercise price. The warrants meet the definition of derivatives under the guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 815 Derivatives and Hedging (“ASC 815”); however, because these instruments have been determined to be indexed to the Company’s own stock and meet the criteria for equity classification under ASC 815-40 Contracts in Entity’s Own Equity, the warrants have been recorded in shareholders’ equity in the Condensed Consolidated Balance Sheets.
In September 2011, the Company entered into amendments with the counterparties to exchange the original warrants with an exercise price of $20.00 (the “Old Warrants”) with new warrants with an exercise price of $30.00 (the “New Warrants”). Approximately 41.0 million of the Old Warrants were exchanged in the transaction. All other terms and settlement provisions of the Old Warrants remain unchanged in the New Warrants. The New Warrants meet the definition of derivatives under the guidance in ASC 815; however, because these instruments have been determined to be indexed to the Company’s own stock and meet the criteria for equity classification under ASC 815-40, the New Warrants have also been recorded in shareholders’ equity in the Condensed Consolidated Balance Sheets.
The average market value of the Company’s shares did not exceed the exercise price of the New Warrants during the three and nine months ended September 30, 2012. For the three and nine months ended September 30, 2012, the average market value of the Company’s shares exceeded the exercise price of the Old Warrants, and as a result, the Company has included 0.3 million and 0.2 million shares, respectively, in the calculation of diluted earnings per share. For the three and nine months ended September 30, 2011, the average market value of the Company’s shares exceeded the exercise price of the Old Warrants, and as a result, the Company has included 1.2 million and 4.3 million shares, respectively, in the calculation of diluted earnings per share.
On May 10, 2012, the Company announced that its Board of Directors had approved the repurchase of up to $500 million of the Company’s common stock in the open market. During the second quarter of 2012, the repurchase program was completed with approximately 23.4 million shares of common stock being repurchased for approximately $500 million.
Basic and diluted earnings per common share attributable to Mylan Inc. are calculated as follows:
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
(In thousands, except per share amounts)
2012
 
2011
 
2012
 
2011
Basic earnings attributable to Mylan Inc. common shareholders (numerator):
 
 
 
 
 
 
 
Net earnings attributable to Mylan Inc. common shareholders
$
211,257

 
$
156,698

 
$
478,886

 
$
407,319

Shares (denominator):
 
 
 
 
 
 
 
Weighted average common shares outstanding
406,469

 
426,412

 
418,000

 
432,265

Basic earnings per common share attributable to Mylan Inc. common shareholders
$
0.52

 
$
0.37

 
$
1.15

 
$
0.94


Diluted earnings attributable to Mylan Inc. common shareholders (numerator):
 
 
 
 
 
 
 
Net earnings attributable to Mylan Inc. common shareholders
$
211,257

 
$
156,698

 
$
478,886

 
$
407,319

Shares (denominator):
 
 
 
 
 
 
 
Weighted average common shares outstanding
406,469

 
426,412

 
418,000

 
432,265

Stock-based awards and warrants
5,093

 
5,175

 
4,775

 
9,552

Total dilutive shares outstanding
411,562

 
431,587

 
422,775

 
441,817

Diluted earnings per common share attributable to Mylan Inc. common shareholders
$
0.51

 
$
0.36

 
$
1.13

 
$
0.92


Additional stock options and restricted stock awards were outstanding during the periods ended September 30, 2012 and September 30, 2011 but were not included in the computation of diluted earnings per share for each respective period, because the effect would be anti-dilutive. Such anti-dilutive stock options or restricted stock awards represented 5.7 million and 7.1 million shares for the three and nine months ended September 30, 2012, respectively, and 7.5 million and 4.9 million shares for the three and nine months ended September 30, 2011, respectively.